| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $4,373,610 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Huang James | director | 2 | $4.37M | 0 | $0 | $4.37M |
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, …
Over the last 12 months, insiders at Connect Biopharma Holdings Limited have bought $4.37M and sold $0 worth of Connect Biopharma Holdings Limited stock.
On average, over the past 5 years, insiders at Connect Biopharma Holdings Limited have bought $4.37M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Huang James (director) — $4.37M.
The last purchase of 150,000 shares for transaction amount of $371,610 was made by Huang James (director) on 2026‑05‑29.
| 2026-05-29 | Huang James | director | 150,000 0.237% | $2.48 | $371,610 | -16.47% | ||
| 2026-03-31 | Huang James | director | 1.16M 2.7324% | $3.45 | $4M | -15.84% |
| Increased Positions | 20 | +111.11% | 8M | +454.89% |
| Decreased Positions | 6 | -33.33% | 901,946 | -52.97% |
| New Positions | 15 | New | 8M | New |
| Sold Out Positions | 2 | Sold Out | 27,938 | Sold Out |
| Total Postitions | 32 | +77.78% | 9M | +401.92% |